Infinera Corporation (NASDAQ: INFN) today released financial results for its third quarter ended September 28, 2024. GAAP revenue for the quarter was ...
Higher third quarter funds flow from operations of $124.7 million ($1.64 per share) — a 34 percent increase over the third quarter of 2023 on a per share basis 2024 average production expected to be ...
Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year over year to $3.1 billion. Sales for Zepbound, which ...